KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.
EP: 1.Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
EP: 2.APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer
EP: 3.KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer
EP: 4.Exciting Developments in HER2+ Breast Cancer
EP: 5.Current Approaches to Treatment Sequencing in HER2+ Breast Cancer
EP: 6.Unmet Needs and Future Directions in HER2+ Breast Cancer
EP: 7.Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
EP: 8.Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
EP: 9.KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
EP: 10.The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
EP: 11.Unmet Needs and Future Directions in HER2+ Breast Cancer Management
Video content above is prompted by the following:
- Please summarize the KATHERINE trial design, which studied adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy.
- How did efficacy data compare amongst the treatment arms?
- How did the recent 5-year OS analysis results presented at SABCS 2023 compare between arms?
- Please comment on the 8+ year follow up data, including IDFS data from this analysis.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer
August 20th 2024During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.
Read More
